Summary:
ClearNote Health has partnered with Claritev, Inc. to make its Avantect Pancreatic Cancer Test accessible to health plan members within Claritev’s PHCS and MultiPlan Networks, aiming to improve early detection and survival rates for pancreatic cancer.

Key Takeaways:

Expanded Access: Through participation in Claritev’s provider networks, ClearNote Health’s innovative detection technology will reach more patients, improving the chances of early intervention and better outcomes.

Early Detection Focus: The Avantect Pancreatic Cancer Test leverages DNA-based technology and machine learning to detect early indicators of pancreatic cancer, which is often diagnosed at a late stage.

Targeted High-Risk Groups: The test is designed for individuals over 50 with newly diagnosed type 2 diabetes, relevant family history, or genetic predisposition to pancreatic cancer.

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, has announced an agreement with Claritev, Inc., previously MultiPlan, Inc., a technology and data insights company focused on making healthcare more affordable, transparent, and fair for all. As part of the agreement, ClearNote Health’s Avantect Pancreatic Cancer Test will now be available to health plan members accessing Claritev’s national PHCS and MultiPlan Networks. 

Avantect Pancreatic Cancer Test Is Designed for High-Risk Patients

While early detection has vastly improved survival rates for many types of cancer, pancreatic cancer is often diagnosed at an advanced metastatic stage when patients have a five-year survival rate as low as 3%.1 The ClearNote Avantect test is a DNA-based blood test that uses key epigenomic and genomic signals coupled with machine learning to detect the earliest indicators of pancreatic cancer when patients are most likely to benefit from treatment. 

The Avantect Pancreatic Cancer Test was designed for patients at high risk of pancreatic cancer, including those newly diagnosed with type 2 diabetes who are at least 50 years old, as well as those with a relevant family history and/or a genetic predisposition. It detects pancreatic cancer by profiling the epigenomic biomarker 5-hydroxymethylcytosine (5hmC) in cell-free DNA and uses advanced AI algorithms to combine that data with other genomic information. This 5hmC-based approach provides a more comprehensive view of the active biological changes related to tumor development, allowing clinicians to identify cancer far earlier than with conventional methods.

“Participation in Claritev’s PHCS and MultiPlan Networks is another critical commercial milestone that will make it easier for health plan members accessing Claritev’s provider networks to use our innovative early cancer detection technology,” says Dave Mullarkey, CEO at ClearNote Health. “We look forward to working with Claritev to enable early detection of pancreatic cancer in high-risk patients so they can live longer, healthier lives.”

Featured Image: The Avantect Pancreatic Cancer Test is designed for high-risk patients, including those newly diagnosed with type 2 diabetes. Photo: ClearNote Health

Reference

1. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019 Feb;10(1):10-27. doi: 10.14740/wjon1166.